Accessibility Menu
Prestige Consumer Healthcare Stock Quote

Prestige Consumer Healthcare (NYSE: PBH)

$59.96
(0.7%)
+0.41
Price as of December 1, 2025, 3:58 p.m. ET

KEY DATA POINTS

Current Price
$59.96
Daily Change
(0.7%) +$0.41
Day's Range
$59.46 - $60.77
Previous Close
$59.96
Open
$59.77
Beta
0.47
Volume
19,419
Average Volume
475,046
Market Cap
2.9B
Market Cap / Employee
$59.93M
52wk Range
$57.25 - $90.04
Revenue
-
Gross Margin
0.54%
Dividend Yield
N/A
EPS
$4.03
CAPs Rating
-
Industry
Pharmaceuticals

The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More

Prestige Consumer Healthcare Return vs. S&P

1 Year5 Year5 Year AnnualizedSince IPO
PBH-29.3%+68.34%+10.98%+238%
S&P+12.93%+85.68%+13.18%+469%

Prestige Consumer Healthcare Company Info

Prestige Consumer Healthcare, Inc. engages in the marketing, sale, and distribution of pharmaceutical drugs and consumer products. It operates through the following segments: North American OTC Healthcare and International OTC Healthcare. The North American and International OTC Healthcare segments manages the following brands: BC/Goody's, Beano, Boudreaux's Butt Paste, Chloraseptic, Clear Eyes, Compound W, Debrox, DenTek, Dramamine, Efferdent, Fess, Fleet, Gaviscon, Hydralyte, Luden's, Monistat, Nix, Pedia-Lax, and Summer's Eve. The company was founded in 1996 and is headquartered in Tarrytown, NY.

News & Analysis

Financial Health

General

Q3 2025YOY Change
Revenue$274.11M-3.4%
Gross Profit$146.41M-3.6%
Gross Margin53.41%-0.1%
Market Cap$3.07B-14.1%
Market Cap / Employee$5.12M0.0%
Employees6005.3%
Net Income$42.21M-22.4%
EBITDA$87.33M-5.3%

Currently no data to display

Revenue Growth Rate

Currently no data to display.

Earnings Per Share Growth Rate

Currently no data to display.

Assets

Q3 2025YOY Change
Net Cash$119.11M131.1%
Accounts Receivable$199.00M21.7%
Inventory1591.8%

Liabilities

Q3 2025YOY Change
Long Term Debt$1.03B-2.4%
Short Term Debt$8.62M225.2%

Ratios

Q3 2025YOY Change
Return On Assets5.94%-0.3%
Return On Invested Capital4.90%0.5%

Cash Flow

Q3 2025YOY Change
Free Cash Flow$55.38M-18.3%
Operating Free Cash Flow$57.49M-17.6%

Valuation

MetricQ4 2024Q1 2025Q2 2025Q3 2025YoY Change
Price to Earnings18.3020.0618.7315.48-11.87%
Price to Book2.232.382.151.66-22.14%
Price to Sales3.493.783.552.77-14.71%
Price to Tangible Book Value-3.47-4.06-4.00-3.173.52%
Price to Free Cash Flow TTM15.7017.6914.8612.03-15.00%
Enterprise Value to EBITDA49.3848.5561.4745.76-8.50%
Free Cash Flow Yield6.4%5.7%6.7%8.3%17.64%
Return on Equity12.6%12.3%12.0%11.3%-10.41%
Total Debt$1.03B$1.04B$1.04B$1.04B-1.87%

No results found

No podcast episodes available.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.